CENTENE CORP

Centene insider sale: Koster sells 56,500 shares at $66.90—small profit, routine liquidity move, not a warning for investors.

Centene insider sale: Christopher Koster sells 47,603 shares amid CFO transition. Investors weigh routine move against strong Medicaid/Medicare fundamentals and 124% YTD upside.

Insider sales surge at Centene Corp: execs dump 30K+ shares while phantom stock trades rise—short‑term volatility, long‑term stability. Invest wisely.

Centene insider Burdick sells 80k shares—routine liquidity move, no impact on stock outlook.

Centene insider sale: Carson Michael A’s 604 phantom‑stock units sell‑off shows executive confidence, signals stable Medicaid revenue, and highlights upcoming vesting impact for investors.

Centene insider buying signals reveal confidence in Medicaid growth; key non‑executive purchases suggest undervaluation and a potential buying catalyst for defensive healthcare investors.

Centene insider sale: Chief People Officer Tanyá McNally sells 964 shares amid strong market sentiment and growing community‑first strategy.

Centene insider moves: CEO sells 36k shares, yet controller keeps 29k+ holdings—what this means for investor confidence and Medicaid strategy.

Centene insider buying surge shows execs betting on upside; investors weigh bullish signals against short‑term losses and future earnings prospects.

Insider buying shows Centene’s execs trust its long‑term Medicaid model – CEO, CFO, and CPO pile on shares, hinting at confidence amid policy swings.